Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $52.00

Amylyx Pharmaceuticals (NASDAQ:AMLX) had its price objective boosted by investment analysts at Robert W. Baird from $28.00 to $52.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s price target indicates a potential upside of 33.71% from the stock’s current price.

A number of other equities research analysts have also commented on the company. Guggenheim lifted their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, June 25th. HC Wainwright increased their price objective on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Mizuho increased their price target on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, Wolfe Research raised shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Amylyx Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $36.25.

Amylyx Pharmaceuticals Trading Up 0.8%

NASDAQ AMLX traded up $0.29 during trading hours on Wednesday, hitting $38.89. 3,483,750 shares of the company’s stock were exchanged, compared to its average volume of 1,607,203. The stock has a 50-day simple moving average of $19.38 and a 200 day simple moving average of $16.35. The firm has a market cap of $4.33 billion, a price-to-earnings ratio of -27.20 and a beta of -0.21. Amylyx Pharmaceuticals has a 1-year low of $7.96 and a 1-year high of $39.93.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). On average, sell-side analysts anticipate that Amylyx Pharmaceuticals will post -1.45 earnings per share for the current fiscal year.

Insider Transactions at Amylyx Pharmaceuticals

In other news, insider Gina Mazzariello sold 15,000 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the transaction, the insider directly owned 194,090 shares in the company, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. KBC Group NV purchased a new position in shares of Amylyx Pharmaceuticals in the first quarter valued at about $26,000. Meeder Asset Management Inc. purchased a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter worth about $25,000. State of Wyoming bought a new position in shares of Amylyx Pharmaceuticals during the second quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd raised its stake in Amylyx Pharmaceuticals by 954.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock valued at $47,000 after buying an additional 3,493 shares during the last quarter. Finally, California State Teachers Retirement System bought a new position in Amylyx Pharmaceuticals in the 2nd quarter worth about $28,000. 95.84% of the stock is currently owned by institutional investors.

Amylyx Pharmaceuticals News Summary

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Avexitide achieved the primary endpoint in the Phase 3 LUCIDITY trial for post-bariatric hypoglycemia, reducing hypoglycemic events by 55%. The result strengthens the case for an FDA filing by the end of 2026 and improves the drug’s potential commercial value. AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
• Positive Sentiment: Analysts raised their outlook for Amylyx. HC Wainwright maintained a Buy rating and a $55 price target while increasing its EPS forecasts to $3.22 for 2029 and $6.40 for 2030, reflecting expectations for successful commercialization and substantially higher future revenue. HC Wainwright Raises Amylyx Price Target
• Positive Sentiment: Guggenheim raised its price target to $55 from $40 with a Buy rating, while Robert W. Baird increased its target to $52 from $28 and assigned an Outperform rating. Wolfe Research also upgraded the shares to Strong Buy, adding to the positive analyst momentum.
• Neutral Sentiment: The clinical success has pushed AMLX toward regulatory and commercial execution milestones. Investors will now focus on additional LUCIDITY data, the FDA filing, approval prospects and Amylyx’s ability to establish avexitide commercially.
• Negative Sentiment: Amylyx priced an upsized public offering of 14.09 million shares at $35.50 per share, expected to raise approximately $500 million before expenses. Underwriters may purchase another 2.11 million shares, creating potential dilution and adding supply near the offering price. Amylyx Prices Upsized $500 Million Offering

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research has centered on therapies intended to protect nerve cells and address the underlying biology of conditions such as amyotrophic lateral sclerosis (ALS) and other serious neurological disorders.

Amylyx’s lead product, AMX0035, was marketed in the United States as Relyvrio and in Canada as Albrioza for the treatment of ALS. Following results from a confirmatory clinical trial that did not meet its objectives, the company announced the voluntary withdrawal of the product from the market in 2024.